I have developed an approach to science that utilizes multiple stem cell-based platforms to answer basic biological questions and combat human disease. My current research portfolio is a direct reflection of my evolution as a scientist in which my early studies of hematopoietic development led to the generation of useful tools and reagents as well as methodologies and insights that synergized into a potent platform in the emerging and rapidly expanding field of pluripotent stem cell biology. My group is composed of dynamic and passionate young researchers and together we have impacted the following areas of investigation:
1.) Developmental hematopoiesis
2.) The generation, culture, and directed differentiation of pluripotent stem cells
3.) Pluripotent stem cell-based modeling of hematopoiesis: a Platform for Production of Transfusable Human Blood Cells
4.) Pluripotent Stem Cell Modeling of Human Disease: The ‘Clinical Trial in a Test Tube’: Sickle Cell Anemia; Amyloidosis
5.) Understanding the molecular and functional basis of exceptional longevity: Dissecting resistance to aging-related disease
Diversity, Equity, Inclusion and Accessibility
As a first generation student, the product of a broken home in a low resource setting, and someone fortunate enough to have overcome many barriers on the path to a career in academia, I am deeply committed to diversity, equity and inclusion efforts to broaden the spectrum of those able to access a career in science and medicine.
Mentorship As a Driver of DEI:
My success as an independent investigator in an extraordinarily competitive branch of science is the direct result of the thoughtful and effective mentorship I have received throughout my career. As such, I understand the critical importance of mentorship, and it has been the foundation upon which I built my lab and surrounding Center for Regenerative Medicine (CReM), the emphasis point in my role as the Director of Research in my Division, and is central to my philosophy in training the next great diverse generation of scientists and clinicians. In accordance with my belief that diverse teams are more impactful and productive, my past trainees have included an individual from a nomadic family in Africa who had been greatly impacted by the HIV epidemic, a refugee from Myanmar (Burma), as well as many first generation students from modest backgrounds…all who have gone on to achieve tremendous success and become exceptional mentors themselves.
A Focus on Diseases That Directly Impact our Surrounding, Underserved Community:
At the CReM, we focus on diseases that directly impact our surrounding underserved community, as one of our main charges is to bring cutting edge, transformative research to the masses. In essence, we like to think that we perform ‘research with reach’ that we hope has the ability to one day transform the lives of all patients here at Boston Medical Center (BMC) and the world, regardless of race, gender, sexual orientation or socio-economic status. One of our goals is to revolutionize the care of patients living with Sickle Cell Disease (SCD), and to one day completely cure the disorder. But there are tremendous health disparities surrounding SCD—although it’s the most common genetic disease worldwide, research has been chronically underfunded, in part due to systemic racism. As a countermeasure, BMC has pulled together a group of world experts in the field, and we all share the vision of better patient care and eventually, a world without sickle cell disease. That mission – that mindset – is unique and gets right to the heart of health equity; Our goal is to remove healthcare obstacles and to give every person the chance to live their healthiest, fullest life. Lastly, although there are very exciting, emerging therapies that may make this possible, a personal charge for myself is also to ensure that these emerging, potentially transformative therapies will be accessible to all: https://www.ted.com/talks/george_murphy_miracle_cures_won_t_answer_your_prayers_if_you_re_poor
Equity and Inclusion Efforts During the COVID-19 Pandemic:
At the height of the pandemic, when rates of infection were skyrocketing, when everything was shut down including most academic centers, when it was virtually impossible to get a COVID test in an appreciable time frame in order to make critical care decisions and isolate those that were infected, I led a Team that mobilized and repurposed ourselves and our center, to build our own FDA approved COVID test, from easily sourced materials that could be found in any lab, in 7 days with a testing turn around time of less than 24 hours. And in true BMC fashion, as soon as we accomplished this, we immediately began to share this information, this ‘blueprint’ for how to run the test, throughout Boston and around the World. As a safety net hospital, our underserved patient population often goes without access to state-of-the-art clinical trials and in this case, rapid COVID testing. This initiative was one of the first of its kind in the country and allowed all of our patients, regardless of socio-economic status, to access rapidly emerging technology leading to more effective care for COVID's most vulnerable victims:
Vanuytsel K, Mithal A, Giadone RM, Yeung AK, Matte TM, Dowrey TW, Werder RB, Miller GJ, Miller NS, Andry CD, Murphy GJ. (2020) Rapid implementation of a SARS-CoV-2 diagnostic quantitative real-time PCR test with emergency use authorization at a large academic safety net hospital. Med Cell Press.
Other Efforts:
Anti-Racism Committee, Center for Regenerative Medicine (CReM), BUSM
Anti-Racism Steering Committee, Division of Hematology-Oncology, BUSM
Member
Boston University
Pulmonary Center
Co-Director
Boston University
Center for Regenerative Medicine
Member
Boston University
Center of Excellence in Sickle Cell Disease
Member
Boston University
Evans Center for Interdisciplinary Biomedical Research
Boston Medical Center
Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
Member
Boston University
Genome Science Institute
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
Understanding the Symbiosis Between Megakaryocytes and the Lung Microenvironment09/01/2020 - 08/31/2024 (Key Person / Mentor)
NIH/National Heart, Lung, and Blood Institute5F30HL154552-03
Understanding the impact of group 2 innate lymphoid cells on airway epithelial regeneration and repair04/01/2022 - 03/31/2024 (Key Person / Mentor)
NIH/National Heart, Lung, and Blood Institute5F31HL162493-02
2021 ASH Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) Award07/01/2021 - 06/30/2022 (Key Person / Mentor)
American Society of Hematology
Defining the role of the AHR in Blood Cell Specification01/01/2016 - 11/30/2021 (Multi-PI)
PI:
George J. Murphy, PhDNIH/National Institute of Environmental Health Sciences5R01ES025409-05
Globin Gene Expression in Sickle Cell Genotype-Specific iPS cells07/05/2011 - 06/30/2017 (Multi-PI)
PI:
George J. Murphy, PhDNIH/National Heart, Lung, and Blood Institute5U01HL107443-05
Stress Granules and the Biology of TDP-4301/01/2016 - 12/31/2016 (Multi-PI)
PI:
George J. Murphy, PhDNIH/National Institute of Environmental Health Sciences4R01ES020395-05
Globin Gene Expression in Sickle Cell Genotype-Specific iPS cells07/05/2011 - 06/30/2016 (Co-Investigator)
PI:
Martin H. Steinberg, MDNIH/National Heart, Lung, and Blood Institute1U01HL107443-01
Stress Granules and the Biology of TDP-4303/01/2012 - 12/31/2015 (Co-Investigator)
PI:
Benjamin Wolozin, MD, PhDNIH/National Institute of Environmental Health Sciences5R01ES020395-04
Boston University Clinical and Translational Science Award (CTSA) Program UL105/01/2008 - 04/30/2013 (PI of Sub-Project / SP)
PI:
David M. Center, MDNIH/National Center for Health Research Resources3UL1RR025771-04
Understanding Hepatic Proteostasis in Systemic Amyloid Diseases07/14/2020 - 03/31/2023 (PI)
Scripps Research Institute National Institutes
Identifying protective omics profiles in centenarians and translating these int…09/15/2019 - 04/30/2022 (PI)
Trustees of Boston University NIH-NIA5UH2AG064704-02
Mechanisms of cis-acting HbF regulation in sickle cell anemia04/01/2017 - 03/31/2022 (PI)
NIH-NHLBI5R01HL133350-03
Large scale, cost-efficient screening and detection of SARS-05/01/2020 - 12/31/2021 (PI)
Harvard Medical School MLSC
Defining the role of the AHR in Blood Cell Specification01/01/2016 - 11/30/2021 (PI)
Trustees of Boston University NIH-NIEHS
iPSC-based Modeling and Therapeutic Intervention In Sickle Cell Disease09/23/2019 - 09/22/2020 (PI)
Beam Therapeutics
Megakaryocyte Transcription Factor Activation to Enhance In Vitro Platelet Production from Humans IP09/10/2015 - 05/31/2019 (PI)
Children's Hospital NIH-NHLBI5R01HL130793-04
Targeting Endogenous Signaling Pathways to Amliorate Systemic Amyloidoses09/08/2014 - 06/30/2018 (PI)
The Scripps Research Institute NIH-NIDDK
iPSC-based Modeling and Therapeutic Intervention in Sickle Cell Disease12/15/2016 - 12/14/2017 (PI)
Incyte Corporation
Globin Gene Expression in Sickle Cell Genotype-Specific iPS Cells07/05/2011 - 06/30/2017 (PI)
Trustees of Boston University NIH-NHLBI
Showing 10 of 14 results.
Show All Results
Pluripotent stem cells in the modeling of blood disease and the production of transfusable human red
07/01/2013 - 06/30/2015 (PI)
National Blood Fdtn
Induced Pluripotent Stem Cell Modeling of Human Hereditary Amyloidosis
01/01/2012 - 12/31/2014 (PI)
Amyloidosis Foundation
iPS Cells: Novel Applications for Thrombocytopania
07/01/2011 - 06/30/2013 (PI)
American Society of Hematology
Characterization of human hematopoietic and endodermal progenitors derived from iPS cells free of re
09/30/2009 - 08/31/2011 (PI)
Trustees of Boston University NIH-NHLBI
Showing 10 of 25 results.
Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
Karagiannis TT, Dowrey TW, Villacorta-Martin C, Montano M, Reed E, Belkina AC, Andersen SL, Perls TT, Monti S, Murphy GJ, Sebastiani P. Multi-modal profiling of peripheral blood cells across the human lifespan reveals distinct immune cell signatures of aging and longevity. EBioMedicine. 2023 Apr; 90:104514.View Related Profiles. PMID: 37005201; DOI: 10.1016/j.ebiom.2023.104514;
-
Heinze D, Park S, McCracken A, Haratianfar M, Lindstrom J, Villacorta-Martin C, Mithal A, Wang F, Yang MW, Murphy G, Mostoslavsky G. Notch activation during early mesoderm induction modulates emergence of the T/NK cell lineage from human iPSCs. Stem Cell Reports. 2022 Dec 13; 17(12):2610-2628.View Related Profiles. PMID: 36332629; PMCID: PMC9768581; DOI: 10.1016/j.stemcr.2022.10.007;
-
Sae-Lee W, McCafferty CL, Verbeke EJ, Havugimana PC, Papoulas O, McWhite CD, Houser JR, Vanuytsel K, Murphy GJ, Drew K, Emili A, Taylor DW, Marcotte EM. The protein organization of a red blood cell. Cell Rep. 2022 Jul 19; 40(3):111103.View Related Profiles. PMID: 35858567; PMCID: PMC9764456; DOI: 10.1016/j.celrep.2022.111103;
-
Teo WW, Cao X, Wu CS, Tan HK, Zhou Q, Gao C, Vanuytsel K, Kumar SS, Murphy GJ, Yang H, Chai L, Tenen DG. Non-coding RNA LEVER sequestration of PRC2 can mediate long range gene regulation. Commun Biol. 2022 Apr 11; 5(1):343.View Related Profiles. PMID: 35411071; PMCID: PMC9001699; DOI: 10.1038/s42003-022-03250-x;
-
Vanuytsel K, Yeung AK, Dowrey TW, Murphy GJ, Belkina AC. CPHEN-013: Comprehensive phenotyping of hematopoietic stem and progenitor cells in the human fetal liver. Cytometry A. 2022 Nov; 101(11):903-908.View Related Profiles. PMID: 35253987
-
Vanuytsel K, Villacorta-Martin C, Lindstrom-Vautrin J, Wang Z, Garcia-Beltran WF, Vrbanac V, Parsons D, Lam EC, Matte TM, Dowrey TW, Kumar SS, Li M, Wang F, Yeung AK, Mostoslavsky G, Dries R, Campbell JD, Belkina AC, Balazs AB, Murphy GJ. Multi-modal profiling of human fetal liver hematopoietic stem cells reveals the molecular signature of engraftment. Nat Commun. 2022 03 01; 13(1):1103.View Related Profiles. PMID: 35232959; PMCID: PMC8888592; DOI: 10.1038/s41467-022-28616-x;
-
Sun Y, Habara A, Le CQ, Nguyen N, Chen R, Murphy GJ, Chui DHK, Steinberg MH, Cui S. Pharmacologic induction of PGC-1a stimulates fetal haemoglobin gene expression. Br J Haematol. 2022 Apr; 197(1):97-109.View Related Profiles. PMID: 35118652
-
Giadone RM, Ghosh, S, Murphy GJ. Editor(s): Alexander Birbrair, in Advances in Stem Cell Biology, Novel Concepts in iPSC Disease Modeling. Patient-specific induced pluripotent stem cells for understanding and assessing novel therapeutics for multisystem transthyretin amyloid disease. Academic Press, Elsevier. London. 2022; 15:105-122. View Publication
-
Blakemore D, Vilaplana-Lopera N, Almaghrabi R, Gonzalez E, Moya M, Ward C, Murphy G, Gambus A, Petermann E, Stewart GS, García P. MYBL2 and ATM suppress replication stress in pluripotent stem cells. EMBO Rep. 2021 05 05; 22(5):e51120. PMID: 33779025; PMCID: PMC8097389; DOI: 10.15252/embr.202051120;
-
Showing 10 of 51 results.
Show More
-
Giadone RM, Mithal A, Miller GJ, Matte TM, Yeung AK, Dowrey TW, Werder RB, Miller NS, Andry CD, Vanuytsel K, Murphy GJ. qRT-PCR Platforms for Diagnosing and Reporting SARS-CoV-2 Infection in Human Samples. STAR Protoc. 2020 Sep 18; 1(2):100102.View Related Profiles. PMID: 32954369; PMCID: PMC7490627; DOI: 10.1016/j.xpro.2020.100102;
-
Giadone RM, Liberti DC, Matte TM, Rosarda JD, Torres-Arancivia C, Ghosh S, Diedrich JK, Pankow S, Skvir N, Jean JC, Yates JR, Wilson AA, Connors LH, Kotton DN, Wiseman RL, Murphy GJ. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease. Stem Cell Reports. 2020 08 11; 15(2):515-528.View Related Profiles. PMID: 32735824; PMCID: PMC7419739; DOI: 10.1016/j.stemcr.2020.07.003;
-
Vanuytsel K, Mithal A, Giadone RM, Yeung AK, Matte TM, Dowrey TW, Werder RB, Miller GJ, Miller NS, Andry CD, Murphy GJ. Rapid Implementation of a SARS-CoV-2 Diagnostic Quantitative Real-Time PCR Test with Emergency Use Authorization at a Large Academic Safety Net Hospital. Med (N Y). 2020 Dec 18; 1(1):152-157.e3.View Related Profiles. PMID: 32838351; PMCID: PMC7235561; DOI: 10.1016/j.medj.2020.05.001;
-
Kanchan K, Iyer K, Yanek LR, Carcamo-Orive I, Taub MA, Malley C, Baldwin K, Becker LC, Broeckel U, Cheng L, Cowan C, D'Antonio M, Frazer KA, Quertermous T, Mostoslavsky G, Murphy G, Rabinovitch M, Rader DJ, Steinberg MH, Topol E, Yang W, Knowles JW, Jaquish CE, Ruczinski I, Mathias RA. Genomic integrity of human induced pluripotent stem cells across nine studies in the NHLBI NextGen program. Stem Cell Res. 2020 07; 46:101803.View Related Profiles. PMID: 32442913; PMCID: PMC7575060; DOI: 10.1016/j.scr.2020.101803;
-
-
Steinberg MH, Kumar S, Murphy GJ, Vanuytsel K. Sickle cell disease in the era of precision medicine: looking to the future. Expert Review of Precision Medicine and Drug Development
Personalized medicine in drug development and clinical practice. 2019; (6):357-367. View Publication
-
-
Vanuytsel K, Steinberg MH, Murphy GJ. In: Haruhisa Inoue, Yukio Nakamura (Eds.), Medical Applications of iPS Cells.
https://doi.org/10.1007/978-981-13-3672-0. Recapitulating Hematopoietic Development in a Dish. Springer Nature Singapore Pte Ltd. 2019. 2019; 45-71. View Publication
-
Seo H, Chen SJ, Hashimoto K, Endo H, Nishi Y, Ohta A, Yamamoto T, Hotta A, Sawaguchi A, Hayashi H, Koseki N, Murphy GJ, Fukuda K, Sugimoto N, Eto K. A ß1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. Blood Adv. 2018 09 11; 2(17):2262-2272. PMID: 30206099; PMCID: PMC6134216; DOI: 10.1182/bloodadvances.2018019547;
-
-
Ward C, Volpe G, Cauchy P, Ptasinska A, Almaghrabi R, Blakemore D, Nafria M, Kestner D, Frampton J, Murphy G, Buganim Y, Kaji K, García P. Fine-Tuning Mybl2 Is Required for Proper Mesenchymal-to-Epithelial Transition during Somatic Reprogramming. Cell Rep. 2018 08 07; 24(6):1496-1511.e8. PMID: 30089261; PMCID: PMC6092268; DOI: 10.1016/j.celrep.2018.07.026;
-
Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018 Sep; 25(3):148-155.View Related Profiles. PMID: 30032658; PMCID: PMC6319917; DOI: 10.1080/13506129.2018.1489228;
-
Leung A, Zulick E, Skvir N, Vanuytsel K, Morrison TA, Naing ZH, Wang Z, Dai Y, Chui DHK, Steinberg MH, Sherr DH, Murphy GJ. Notch and Aryl Hydrocarbon Receptor Signaling Impact Definitive Hematopoiesis from Human Pluripotent Stem Cells. Stem Cells. 2018 07; 36(7):1004-1019.View Related Profiles. PMID: 29569827; PMCID: PMC6099224; DOI: 10.1002/stem.2822;
-
Morrison TA, Wilcox I, Luo HY, Farrell JJ, Kurita R, Nakamura Y, Murphy GJ, Cui S, Steinberg MH, Chui DHK. A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression. Blood Cells Mol Dis. 2018 03; 69:1-9.View Related Profiles. PMID: 29227829; PMCID: PMC5783741; DOI: 10.1016/j.bcmd.2017.11.003;
-
Shaikho EM, Farrell JJ, Alsultan A, Qutub H, Al-Ali AK, Figueiredo MS, Chui DHK, Farrer LA, Murphy GJ, Mostoslavsky G, Sebastiani P, Steinberg MH. A phased SNP-based classification of sickle cell anemia HBB haplotypes. BMC Genomics. 2017 Aug 11; 18(1):608.View Related Profiles. PMID: 28800727; PMCID: PMC5553663; DOI: 10.1186/s12864-017-4013-y;
-
Ash PEA, Stanford EA, Al Abdulatif A, Ramirez-Cardenas A, Ballance HI, Boudeau S, Jeh A, Murithi JM, Tripodis Y, Murphy GJ, Sherr DH, Wolozin B. Dioxins and related environmental contaminants increase TDP-43 levels. Mol Neurodegener. 2017 05 05; 12(1):35.View Related Profiles. PMID: 28476168; PMCID: PMC5420162; DOI: 10.1186/s13024-017-0177-9;
-
Park S, Gianotti-Sommer A, Molina-Estevez FJ, Vanuytsel K, Skvir N, Leung A, Rozelle SS, Shaikho EM, Weir I, Jiang Z, Luo HY, Chui DHK, Figueiredo MS, Alsultan A, Al-Ali A, Sebastiani P, Steinberg MH, Mostoslavsky G, Murphy GJ. A Comprehensive, Ethnically Diverse Library of Sickle Cell Disease-Specific Induced Pluripotent Stem Cells. Stem Cell Reports. 2017 Apr 11; 8(4):1076-1085.View Related Profiles. PMID: 28111279; PMCID: PMC5390092; DOI: 10.1016/j.stemcr.2016.12.017;
-
Vathipadiekal V, Farrell JJ, Wang S, Edward HL, Shappell H, Al-Rubaish AM, Al-Muhanna F, Naserullah Z, Alsuliman A, Qutub HO, Simkin I, Farrer LA, Jiang Z, Luo HY, Huang S, Mostoslavsky G, Murphy GJ, Patra PK, Chui DH, Alsultan A, Al-Ali AK, Sebastiani P, Steinberg MH. A candidate transacting modulator of fetal hemoglobin gene expression in the Arab-Indian haplotype of sickle cell anemia. Am J Hematol. 2016 Nov; 91(11):1118-1122.View Related Profiles. PMID: 27501013; PMCID: PMC5072989; DOI: 10.1002/ajh.24527;
-
-
Stanford EA, Wang Z, Novikov O, Mulas F, Landesman-Bollag E, Monti S, Smith BW, Seldin DC, Murphy GJ, Sherr DH. The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. BMC Biol. 2016 Mar 16; 14:20.View Related Profiles. PMID: 26984638; PMCID: PMC4794823; DOI: 10.1186/s12915-016-0240-y;
-
-
-
Wilson AA, Ying L, Liesa M, Segeritz CP, Mills JA, Shen SS, Jean J, Lonza GC, Liberti DC, Lang AH, Nazaire J, Gower AC, Müeller FJ, Mehta P, Ordóñez A, Lomas DA, Vallier L, Murphy GJ, Mostoslavsky G, Spira A, Shirihai OS, Ramirez MI, Gadue P, Kotton DN. Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells. Stem Cell Reports. 2015 May 12; 4(5):873-85.View Related Profiles. PMID: 25843048; PMCID: PMC4437473; DOI: 10.1016/j.stemcr.2015.02.021;
-
-
-
Leung A, Nah SK, Reid W, Ebata A, Koch CM, Monti S, Genereux JC, Wiseman RL, Wolozin B, Connors LH, Berk JL, Seldin DC, Mostoslavsky G, Kotton DN, Murphy GJ. Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis. Stem Cell Reports. 2013; 1(5):451-63.View Related Profiles. PMID: 24286032; PMCID: PMC3841264; DOI: 10.1016/j.stemcr.2013.10.003;
-
Smith BW, Rozelle SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, Chui DH, Steinberg MH, Frelinger AL, Michelson AD, Theberge R, McComb ME, Costello CE, Kotton DN, Mostoslavsky G, Sherr DH, Murphy GJ. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood. 2013 Jul 18; 122(3):376-85.View Related Profiles. PMID: 23723449; PMCID: PMC3716202; DOI: 10.1182/blood-2012-11-466722;
-
Sommer AG, Rozelle SS, Sullivan S, Mills JA, Park SM, Smith BW, Iyer AM, French DL, Kotton DN, Gadue P, Murphy GJ, Mostoslavsky G. Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector. J Vis Exp. 2012; (68).View Related Profiles. PMID: 23149977; PMCID: PMC3499070; DOI: 10.3791/4327;
-
Christodoulou C, Longmire TA, Shen SS, Bourdon A, Sommer CA, Gadue P, Spira A, Gouon-Evans V, Murphy GJ, Mostoslavsky G, Kotton DN. Mouse ES and iPS cells can form similar definitive endoderm despite differences in imprinted genes. J Clin Invest. 2011 Jun; 121(6):2313-25.View Related Profiles. PMID: 21537085; PMCID: PMC3104741; DOI: 10.1172/JCI43853;
-
Somers A, Jean JC, Sommer CA, Omari A, Ford CC, Mills JA, Ying L, Sommer AG, Jean JM, Smith BW, Lafyatis R, Demierre MF, Weiss DJ, French DL, Gadue P, Murphy GJ, Mostoslavsky G, Kotton DN. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells. 2010 Oct; 28(10):1728-40.View Related Profiles. PMID: 20715179; PMCID: PMC3422663; DOI: 10.1002/stem.495;
-
Sommer CA, Sommer AG, Longmire TA, Christodoulou C, Thomas DD, Gostissa M, Alt FW, Murphy GJ, Kotton DN, Mostoslavsky G. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells. 2010 Jan; 28(1):64-74.View Related Profiles. PMID: 19904830; PMCID: PMC4848036; DOI: 10.1002/stem.255;
-
Wilson AA, Murphy GJ, Hamakawa H, Kwok LW, Srinivasan S, Hovav AH, Mulligan RC, Amar S, Suki B, Kotton DN. Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. J Clin Invest. 2010 Jan; 120(1):379-89.View Related Profiles. PMID: 20038801; PMCID: PMC2798672; DOI: 10.1172/JCI36666;
-
-
Murphy GJ, Mostoslavsky G, Kotton DN, Mulligan RC. Exogenous control of mammalian gene expression via modulation of translational termination. Nat Med. 2006 Sep; 12(9):1093-9.View Related Profiles. PMID: 16892063
-
Göttgens B, Broccardo C, Sanchez MJ, Deveaux S, Murphy G, Göthert JR, Kotsopoulou E, Kinston S, Delaney L, Piltz S, Barton LM, Knezevic K, Erber WN, Begley CG, Frampton J, Green AR. The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1. Mol Cell Biol. 2004 Mar; 24(5):1870-83. PMID: 14966269; PMCID: PMC350551
-
Gaur M, Murphy GJ, Frampton J, Leavitt AD. Using retroviruses to express genes in primary megakaryocyte lineage cells. Methods Mol Biol. 2004; 273:381-96. PMID: 15308813
-
Emambokus NR, Murphy GJ, Frampton J. Manipulation of gene expression in megakaryocytes. Methods Mol Biol. 2004; 273:33-56. PMID: 15308792
-
Murphy GJ, Göttgens B, Vegiopoulos A, Sanchez MJ, Leavitt AD, Watson SP, Green AR, Frampton J. Manipulation of mouse hematopoietic progenitors by specific retroviral infection. J Biol Chem. 2003 Oct 31; 278(44):43556-63. PMID: 12928443
-
Gaur M, Murphy GJ, deSauvage FJ, Leavitt AD. Characterization of Mpl mutants using primary megakaryocyte-lineage cells from mpl(-/-) mice: a new system for Mpl structure-function studies. Blood. 2001 Mar 15; 97(6):1653-61. PMID: 11238104
-
Shiraga M, Ritchie A, Aidoudi S, Baron V, Wilcox D, White G, Ybarrondo B, Murphy G, Leavitt A, Shattil S. Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling. J Cell Biol. 1999 Dec 27; 147(7):1419-30. PMID: 10613901; PMCID: PMC2174239
-
Murphy GJ, Leavitt AD. A model for studying megakaryocyte development and biology. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):3065-70. PMID: 10077637; PMCID: PMC15895
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 1999 | 2 |
| 2001 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2006 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 7 |
| 2023 | 1 |
Miracle cures won't answer your prayers...if you're poor. TEDx Talk
iPSC-based modeling of exceptional longevity: Centenarian Stem Cell Bank
Brewing Blood: Transfusable Stem Cell-Derived Blood Products
CBS News Boston: Brewing Blood
2021 BUSM:
National Academy of Medicine (NAM) Catalyst Award in Healthy Longevity
2020 BUSM:
Massachusetts Pathogen Readiness (MassCPR) Award
2020 BUSM:
Graduate Medical Sciences (GMS) Exceptional Mentoring Award
2013 BUSM:
National Blood Foundation (NBF) Scholar Award
2012 BUSM:
Amyloid Foundation Junior Investigator Award
2011 BUSM:
American Society of Hematology (ASH) Scholar Award
2008 Harvard Medical School:
NIH NRSA Individual Fellowship Award
2002 Oxford University:
Graduate Scholar in Molecular Biology
My success as an independent investigator in an extraordinarily competitive branch of science is the direct result of the thoughtful and effective mentorship I have received throughout my career. As such, I understand the critical importance of mentorship, and it has been the foundation upon which I built my lab and surrounding Center, the emphasis point in my role as the Director of Research in my Division, and is central to my philosophy in training the next great generation of scientists and clinicians. Although I am a mid-career investigator, I have had extensive experience with scientific leadership. Along with my two colleagues Gustavo Mostoslavsky MD/PhD and Darrell Kotton MD, I founded and direct the Boston University and Boston Medical Center’s Center for Regenerative Medicine (CReM) (www.bumc.bu.edu/stemcells), where 50 scientists including 12 faculty members work together, synergistically in a multi-disciplinary approach to advancing stem cell biology and regenerative medicine. In founding the CReM, I constructed and implemented a strategic plan steeped in guiding principles such as scientific rigor, collegiality, and mentorship. Under my direction, the CReM has been highly successful and has become the number one Center on campus as judged by all metrics of productivity including funding, high impact publications, and the recruitment and placement of the highest quality trainees. These foundational keys are also directly imparted to my students and trainees. My previous students and fellows trained in these disciplines have been extremely successful (Sarah S. Rozelle: completed her PhD, became a postdoctoral fellow at Harvard Medical School, and is now an Assistant Professor at UMASS Lowell; Brenden W. Smith: completed his PhD in June 2016, became a staff scientist and presidential postdoctoral fellow at Novartis, and is now the lead scientist in drug delivery at Platelet Biogenesis; Elizabeth Zulick completed her postdoctoral fellowship, attained am Assistant Professorship at Northeastern University, and now directs the entire Biology and Biotechnology platforms at the University, Kim Vanuytsel was recently promoted to Research Assistant Professor in the Division of Hematology-Oncology in the Department of Medicine at BUSM after the completion of a highly successful postdoctoral fellowship within my group). All of the research technicians who have passed through my lab have gone onto PhD or MD programs, as again, one of the CReMs founding principles is that of quality mentorship at all levels. I am also a sought after dissertation advisor for PhD and MD/PhD students having mentored more than 15 students in this capacity including those at nearby institutions including Harvard.
I am the recent recipient of an award for exceptional mentorship by Graduate Medical Sciences and the PhD program here at the University. I have also been involved in the development of the integrated Program in Biomedical Sciences (PiBS) graduate program, having taught several courses including a Stem Cell and Regenerative Medicine module pioneered by myself and my colleagues in the CReM. I am also a member of the PiBS admissions committee where I have a dedicated interest in recruiting diverse applicants.
Available to Mentor as: (Review Mentor Role Definitions):
-
Advisor
-
Career Mentor
-
Co-Mentor or Peer Mentor
-
Education Mentor
-
Project Mentor
-
Research / Scholarly Mentor
-
Work / Life Integration Mentor